SCHEMBL16335142

SCHEMBL16335142

COc1ccc(Cn2c(=O)c(C)c(-c3ccc(O)cc3C#N)n(C)c2=O)cc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 2/20 0.39
DPP4 P27487 1/20 0.38
ESR1 P03372 2/20 0.38
PDE7A Q13946 2/20 0.37
PDE7B Q9NP56 2/20 0.37
AR P10275 1/20 0.37
KMT2A Q03164 2/20 0.37
FEN1 P39748 1/20 0.37
MEN1 O00255 1/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 3/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 1/20 0.37
KCNJ1 P48048 2/20 0.36
KCNH2 Q12809 2/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15666946 0.87 LMNA (0.42) LMNASMN1; SMN2ALDH1A1ESR1KMT2A
SCHEMBL17200280 0.82 ESR1 (0.48) LMNASMN1; SMN2ALDH1A1KDM4EESR1
SCHEMBL18428422 0.73 ESR1 (0.47) LMNASMN1; SMN2ALDH1A1KDM4EESR1
SCHEMBL18428426 0.73 ESR1 (0.49) LMNASMN1; SMN2ALDH1A1KDM4EESR1
SCHEMBL15666947 0.73 MAPK10 (0.47) LMNASMN1; SMN2ALDH1A1PDE7AKMT2A
SCHEMBL18428428 0.72 ESR1 (0.42) LMNASMN1; SMN2ALDH1A1ESR1KMT2A
SCHEMBL18428421 0.70 PDE7A (0.47) LMNASMN1; SMN2ALDH1A1ESR1PDE7A
SCHEMBL16338221 0.69 DRD1 (0.58) SMN1; SMN2
SCHEMBL17201664 0.67 DRD1 (0.57) SMN1; SMN2ALDH1A1
SCHEMBL17208473 0.66 DRD1 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2026-05-07 US disclosed
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2024-09-26 US disclosed
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2024-04-23 US disclosed
EP-3421462-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2023-04-05 EP disclosed
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2021-09-30 US disclosed
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2021-05-25 US disclosed
US-20200283407-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2020-09-10 US disclosed
US-10696658-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2020-06-30 US disclosed
US-10421744-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2019-09-24 US disclosed
EP-3013813-B1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2019-04-03 EP disclosed
US-9822097-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2017-11-21 US disclosed
US-20170057947-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2017-03-02 US disclosed
US-9527831-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2016-12-27 US disclosed
EP-3013813-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS Pfizer Inc. (US) 2016-05-04 EP disclosed
US-9139561-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2015-09-22 US disclosed
US-9107923-B2 Heteroaromatic compounds and their use as dopamine D1 ligands PFIZER INC. (US) 2015-08-18 US disclosed
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-07-16 US disclosed
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2015-06-25 US disclosed
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER (US) 2015-01-01 US disclosed
WO-2014207601-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS PFIZER INC. (US) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125364-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS HTR6, HTR3C, OPRD1 LMNA 2257/4885SMN1; SMN2 614/4885ALDH1A1 3129/4885
US-20150196561-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS SNCA, DRD1, DRD2 LMNA 4783/4885SMN1; SMN2 2561/4885ALDH1A1 377/4885
US-11964961-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, HTR1D LMNA 2789/4885SMN1; SMN2 1161/4885ALDH1A1 3603/4885
US-10421744-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD1, SNCA, DRD2 LMNA 4835/4885SMN1; SMN2 2812/4885ALDH1A1 300/4885
US-20210300899-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D LMNA 2789/4885SMN1; SMN2 1161/4885ALDH1A1 3603/4885
US-20240317713-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D LMNA 2789/4885SMN1; SMN2 1161/4885ALDH1A1 3603/4885
US-20150005313-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS SNCA, DRD1, DRD2 LMNA 4783/4885SMN1; SMN2 2561/4885ALDH1A1 377/4885
US-20150175573-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, HTR1D LMNA 2789/4885SMN1; SMN2 1161/4885ALDH1A1 3603/4885
US-20200283407-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, DRD1, SNCA LMNA 4821/4885SMN1; SMN2 3330/4885ALDH1A1 267/4885
US-10696658-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD1, SNCA, DRD2 LMNA 4835/4885SMN1; SMN2 2812/4885ALDH1A1 300/4885
US-11014909-B2 Heteroaromatic compounds and their use as dopamine D1 ligands DRD2, DRD1, SNCA LMNA 4821/4885SMN1; SMN2 3330/4885ALDH1A1 267/4885
US-20170057947-A1 HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS DRD2, HTR1D, DRD1 LMNA 2322/4885SMN1; SMN2 1131/4885ALDH1A1 3185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.